What is caba-201?

CABA-201, our lead CARTA candidate, is an investigational fully human CD19 chimeric antigen receptor (CAR) T cell therapy with a 4-1BB co-stimulatory domain currently under development for systemic lupus erythematosus (SLE), myositis, systemic sclerosis, and generalized myasthenia gravis as well as other autoimmune diseases with high unmet need.

What is cabaletta ®?

At Cabaletta, we are committed to transforming the treatment of autoimmune diseases by utilizing our innovative CABA ® platform to develop cell therapy products with the aim of providing deep, durable and potentially curative responses for patients with autoimmune diseases.

What is caba-201 T cell therapy?

It encompasses two strategies: the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach as well as our initial Chimeric AutoAntibody Receptor T (CAART) approach. Our lead CARTA candidate, CABA-201, is an investigational 4-1BB-containing CD19-CAR T cell therapy based on a clinically evaluated fully human CD19 binder.